DNLI vs. PRTA, RGNX, CYTK, QGEN, RGEN, PCVX, EXEL, RVMD, HALO, and KRYS
Should you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Prothena (PRTA), REGENXBIO (RGNX), Cytokinetics (CYTK), Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), Exelixis (EXEL), Revolution Medicines (RVMD), Halozyme Therapeutics (HALO), and Krystal Biotech (KRYS). These companies are all part of the "medical" sector.
Denali Therapeutics (NASDAQ:DNLI) and Prothena (NASDAQ:PRTA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, community ranking, profitability and institutional ownership.
Denali Therapeutics has a net margin of -36.51% compared to Prothena's net margin of -193.17%. Denali Therapeutics' return on equity of -11.46% beat Prothena's return on equity.
Denali Therapeutics has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Prothena has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.
In the previous week, Prothena had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 11 mentions for Prothena and 8 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.15 beat Prothena's score of 0.75 indicating that Denali Therapeutics is being referred to more favorably in the media.
Denali Therapeutics has higher revenue and earnings than Prothena. Denali Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.
Prothena received 161 more outperform votes than Denali Therapeutics when rated by MarketBeat users. Likewise, 70.67% of users gave Prothena an outperform vote while only 67.43% of users gave Denali Therapeutics an outperform vote.
92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 7.9% of Denali Therapeutics shares are owned by insiders. Comparatively, 28.2% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Denali Therapeutics presently has a consensus price target of $40.22, indicating a potential upside of 116.71%. Prothena has a consensus price target of $67.00, indicating a potential upside of 221.96%. Given Prothena's higher probable upside, analysts clearly believe Prothena is more favorable than Denali Therapeutics.
Summary
Denali Therapeutics beats Prothena on 10 of the 18 factors compared between the two stocks.
Get Denali Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Denali Therapeutics Competitors List
Related Companies and Tools
